Related Experiment Video
Updated: Dec 26, 2025

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting
Published on: May 16, 2013
Do asymptomatic clots in children matter?
Sophie Jones1, Paul Monagle2, Fiona Newall3
1Haematology Research Group, Murdoch Children's Research Institute, Melbourne, Australia; Department of Clinical Haematology, The Royal Children's Hospital, Melbourne, Australia; Department of Nursing, The University of Melbourne, Australia.
Insights
Asymptomatic venous thrombosis in children, often linked to central venous catheters, requires careful consideration for treatment. Current evidence is insufficient to definitively guide management, necessitating further research.
Area of Science:
- Pediatric Medicine
- Hematology
- Vascular Medicine
Background:
- Asymptomatic venous thrombosis is a frequent complication in hospitalized children.
- Current guidelines advocate for treating all asymptomatic venous thrombosis, regardless of incidental diagnosis or resolved risk factors.
- The necessity and risks of treating asymptomatic thrombosis in children remain unclear.
Purpose of the Study:
- To review the current evidence on asymptomatic thrombosis in pediatric patients.
- To evaluate the necessity of screening for asymptomatic thrombosis.
- To assess the risk-benefit ratio of treatment and potential long-term morbidity.
Main Methods:
- Literature review of existing evidence on pediatric asymptomatic thrombosis.
- Analysis of data concerning incidence, characteristics, and outcomes.
- Discussion of risk factors, including central venous catheters (CVCs).
Main Results:
- Asymptomatic thrombosis is common in hospitalized children, particularly those with cancer, neonates, and critically ill children.
- Central venous catheters (CVCs) are a frequent association.
- Data on incidence and outcomes are often imprecise, lacking distinction from symptomatic thrombosis.
Conclusions:
- The clinical significance of asymptomatic venous thromboembolism (VTE) in children requires further investigation.
- Prospective studies with extended follow-up are essential to determine optimal management strategies.
- The risk-benefit balance of anticoagulation treatment needs careful evaluation.
Abstract:
Asymptomatic venous thrombosis is a common complication among hospitalised paediatric patients. Previous guidelines recommend the treatment of all asymptomatic venous thrombosis, even when the diagnosis is made incidentally or the risk factor is no longer present. Whether clinicians need to treat all asymptomatic thrombosis in children, given the likelihood of long-term sequelae, is unclear and there are significant risks associated with anticoagulation treatment. Asymptomatic thrombosis in children is most frequently associated with central venous catheters (CVCs). The incidence of asymptomatic CVC-related VTE is highest in cohorts of children with cancer, but also reported in neonates, children with congenital heart disease and critically ill children. There is significant variation in reported rates of CVC-related thrombosis among cohorts of children with different underlying diseases and of various ages. As asymptomatic thrombosis is often an incidental finding, rates of asymptomatic VTE in children are most likely underestimated. Evidence about the incidence, characteristics and long-term outcomes associated with asymptomatic thrombosis in children often lacks precision as data is presented collectively with symptomatic thrombosis. This review discusses the current evidence pertaining to the necessity for screening for asymptomatic thrombosis, the risk benefit ratio of treatment and the risk of long-term morbidity. To confidently determine the clinical significance of asymptomatic VTE in children, prospective studies with extended follow up are needed.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Aneurysm II: Clinical Manifestations and Diagnostic Studies

